Company Profile
BGI Genomics provides research services, comprehensive precision medicine testing solutions, and health management services in China and globally. The company offers DNA sequencing services comprising plant/animal/microbial whole genome re-sequencing and de novo sequencing. Its portfolio also includes human whole genome sequencing, long-read human whole genome resequencing, and whole exome sequencing, epigenetics whole genome bisulfite sequencing and ChIp-Seq, and metagenomics and 16S/18S/ITS sequencing
RNA sequencing, long non-coding RNA sequencing, small RNA sequencing, iso-seq / pacbio transcriptome sequencing. Its portfolio also includes single cell sequencing and high throughput single cell RNA-Seq, spatial transcriptome-stereo-seq, immune repertoire and pre-made library sequencing, and bioinformatics solutions.
Additionally, it offers mass spectrometry, including proteomics, metabolomics, and multi-omics clinical solutions for reproductive health, oncology, infectious disease, and chronic disease.
Founded in 1999 and headquartered in Shenzhen, China, the company was formerly known as Shenzhen BGI Medicine Co., Ltd. before rebranding in 2015. BGI Genomics Co., Ltd. operates as a subsidiary of BGI Group.